We found that genes that were repressed by abrogation of MELK activity (i.e. positively regulated by MELK) were predominantly upregulated in prostate cancer compared to benign tissue and in metastatic compared to primary prostate cancers, confirming our hypothesis that MELK plays a role in cancer progression (Fig 5A). The gene discussed is MELK; the disease is prostate cancer.